CRNX (Crinetics Pharmaceuticals, Inc.) Stock Market Reviews

crown

search

Read and share opinions on CRNX (Crinetics Pharmaceuticals, Inc.) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stock

CRNX

Crinetics Pharmaceuticals, Inc.

clarify Biotechnology

bookmark Healthcare

public United States

Sell Neutral Buy

Latest News

Crinetics Pharmaceuticals Announces November 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nov 10, 2025
Crinetics Pharmaceuticals (CRNX): Valuation in Focus After FDA Approval and Positive PALSONIFY Launch Momentum
Nov 9, 2025
Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q3 Loss, Lags Revenue Estimates
Nov 6, 2025
Crinetics Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update
Nov 6, 2025
Crinetics to Highlight Neuroendocrine Tumor Research Progress at the 2025 North American Neuroendocrine Tumor Society Annual Meeting
Oct 23, 2025
Crinetics Pharmaceuticals Announces October 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Oct 10, 2025
Cantor Fitzgerald Maintains a Buy Rating on Crinetics Pharmaceuticals (CRNX)
Oct 7, 2025
A Look at Crinetics Pharmaceuticals's Valuation Following FDA Approval of PALSONIFY for Acromegaly
Oct 7, 2025
Crinetics Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025
Oct 6, 2025
JMP Backs Crinetics Pharmaceuticals, Inc. (CRNX) With Big Upside Post-Approval
Sep 30, 2025
JPMorgan Lifts PT on Crinetics Pharmaceuticals (CRNX) to $52 From $53, Keeps an Overweight Rating
Sep 30, 2025
Crinetics Pharma (CRNX) Flies 35% Higher on FDA Approval of Acromegaly Drug
Sep 29, 2025
FDA Approves Crinetics Pharma's First Daily Pill For Rare Growth Disorder
Sep 26, 2025
Crinetics Pharmaceuticals Receives FDA Approval for Palsonify to Treat Acromegaly
Sep 25, 2025

Reviews